Key terms

About BDX

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest BDX news

Apr 05 6:52am ET Becton Dickinson announes commercial release of cell sorters Apr 04 7:38pm ET Citi opens 90-day catalyst watch on Becton Dickinson Apr 03 5:47am ET Citi opens ‘positive catalyst watch’ on Becton Dickinson into earnings Apr 01 5:21pm ET AngioDynamics settles litigation with Becton Dickinson Mar 28 9:35pm ET Upcoming Deadline to Share in Becton, Dickinson and Company (BDX) Class Action Settlement Mar 21 6:55am ET Becton Dickinson further increases U.S. syringe production Mar 12 4:55am ET Becton Dickinson management to meet with Jefferies Mar 10 10:37pm ET Becton Dickinson management to meet with Jefferies Mar 04 6:56am ET Becton Dickinson enrolls first patient in IDE study AGILITY Feb 27 7:13am ET Becton Dickinson Executive Retirement and Succession Plan Feb 21 6:51am ET Becton Dickinson enters pact with Camtech to advance cervical cancer screening Feb 15 5:51am ET GD, BDX, SYY: 3 Best Dividend Aristocrats with Plenty of Upside Potential Feb 09 4:49am ET Becton Dickinson Issues Euro and USD Debt Notes Feb 07 4:54am ET Becton Dickinson Launches Billion-Dollar Note Offerings Feb 05 5:29am ET Becton Dickinson price target raised to $305 from $301 at Barclays Feb 04 8:25pm ET Barclays Sticks to Their Buy Rating for Becton Dickinson (BDX) Feb 02 8:10am ET Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), Revvity (RVTY) and Becton Dickinson (BDX) Feb 02 5:41am ET Analysts Are Bullish on These Healthcare Stocks: Quest Diagnostics (DGX), Becton Dickinson (BDX) Feb 01 4:05pm ET Becton Dickinson: Hold Rating Maintained Amid Mixed Performance and Optimistic Outlook Feb 01 6:56am ET Becton Dickinson ups FY24 adjusted EPS view to $12.82-$13.06 from $12.70-$13.00 Feb 01 6:53am ET Becton Dickinson reports Q1 adjusted EPS $2.68, consensus $2.40 Jan 31 8:25pm ET Notable companies reporting before tomorrow’s open Jan 31 12:59pm ET Notable companies reporting before tomorrow’s open Jan 30 6:56am ET Becton Dickinson, Techcyte enter collaboration Jan 27 4:25am ET Becton Dickinson Shareholders Approve Key Proposals Jan 23 6:54am ET Becton Dickinson announces collaboration agreement with Hamilton Jan 12 5:45am ET Becton Dickinson: Strong Buy Rating Amidst Robust Financial Outlook and Strategic Growth Initiatives Jan 09 11:01am ET Becton Dickinson sees shifting of $30M of flu testing revenue from Q1 Jan 09 10:59am ET Becton Dickinson backs FY adjusted EPS view $12.70-$13.00, consensus $12.84 Jan 08 9:02am ET Accelerate Diagnostics price target lowered to $2 from $5 at Craig-Hallum

BDX Financials

1-year income & revenue

Key terms

BDX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

BDX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms